

pubs.acs.org/OrgLett

Letter

Cu(OTf)₂-Catalyzed Intramolecular Radical Cascade Reactions for the **Diversity-Oriented Synthesis of Quinoline-Annulated Polyheterocyclic Frameworks**

Shuo Yuan, Jingya Zhang, Danqing Zhang, Donghui Wei, Jiahui Zuo, Jian Song, Bin Yu,* and Hong-Min Liu*



ABSTRACT: Compound libraries with high levels of structural diversity and novelty could cover underexploited chemical space and thus have been highly pursued in drug discovery. Herein, we report the first $Cu(OTf)_2$ -catalyzed intramolecular radical cascade reactions that enable the diversity-oriented synthesis of quinoline-annulated polyheterocyclic compounds (7 unique scaffolds, 66 examples) in an efficient manner. This work demonstrates an alternative route to access the natural product- and druglike compound collection with high levels of structural diversity and novelty.

he privileged polyheterocyclic compounds containing a quinoline fragment are widely present in numerous natural products and bioactive molecules, and such compounds have proven to possess a wide variety of pharmacological properties, such as anticancer, antiviral, and antiangiogenic activity (Figure 1).¹⁻³ Representative quinoline-containing natural products are trisphaeridine (an alkaloid isolated from amaryllidaceae species with potential antitumor activity), camptothecin (a topoisomerase inhibitor isolated from camptotheca acuminate with remarkable anticancer activity), fagaronine (a benzophenanthridine alkaloid found in zanthoxylum zanthoxyloides with potential antimalarial activity),⁶ and



Figure 1. Selected quinoline-fused polyheterocyclic natural products and bioactive molecules.

distomadine A (a tetracyclic alkaloid isolated from Pseudodistoma aureum with antifungal activity) (Figure 1A). In addition, quinoline-containing polyheterocyclic fragments are also prevalent in bioactive molecules, such as torin 1 (a potent and selective mTOR inhibitor),8 topovale (a Top1 targeting antitumor drug),9 KuFal194 (a highly potent and selective DYRK1A inhibitor),¹⁰ and QL47 (a potent, selective and irreversible BTK inhibitor)¹¹ (Figure 1B). Because of the unique structural features and interesting biological profiles of quinoline-containing polyheterocyclic scaffolds, several synthetic strategies have been developed for the construction of these structurally complex and biologically important scaffolds in recent decades; two main strategies include (a) transitionmetal-catalyzed cyclization reactions of quinoline bearing substrates¹²⁻¹⁴ and (b) transition-metal-catalyzed domino cascade reactions forming the quinoline ring system.¹⁵

Alkynes have been extensively used in organic synthesis, particularly for cyclization reactions.^{18–21} In 2012, Zhu and coworkers successfully obtained indolo[3,2-c]isoquinolinones through Pd-catalyzed intramolecular cascade reactions of alkynes, in which amination, N-demethylation, and amidation

Received: January 13, 2021 Published: February 9, 2021





were involved (Scheme 1A).²² In 2016, Du et al. successfully achieved stepwise synthesis of indolo[3,2-c] isocoumarins

Scheme 1. Intramolecular Cascade Reactions of Alkynes Enabling the Construction of Diverse Polyheterocyclic Scaffolds

(A) Pd-catalyzed intramolecular amination/N-demethylation/amidation sequence



(C) Gold-catalyzed bicyclization of diaryl alkynes



(D) This work: Cu(OTf)2-catalyzed diversity-oriented synthesis of new quinoline-annulated polyheterocyclic



through intramolecular trans-aminocarboxylation of alkynes (Scheme 1B).²³ In 2018, Xu et al. reported a gold-catalyzed bicyclization of diarylacetylenes for the synthesis of indole annulated tetracyclic compounds (Scheme 1C).²⁴ These examples have demonstrated that trapping alkynes by neighboring nucleophilic groups is a viable strategy that enables rapid access to pharmacologically relevant polyheterocyclic scaffolds through cascade reactions.25,26 To date, although several protocols about the efficient synthesis of polyheterocyclic scaffolds through alkyne-based cascade reactions have been disclosed, the versatile one-pot synthetic strategy for the construction of diverse quinoline-containing polyheterocyclic scaffolds is still rare. Moreover, achieving high levels of structural novelty and diversity in an efficient manner is challenging and highly desirable, such compound library covers underexplored chemical space and thus is a key to success in new drug discovery campaign. In continuation with our previous work on the synthesis of biologically important heterocycles, 2^{7-33} we herein report the Cu(OTf)₂-catalyzed domino 6-endo-dig cyclization/C-C coupling reaction sequence that enables the efficient synthesis of architecturally diverse and novel quinoline-annulated polyheterocyclic scaffolds (7 unique scaffolds, 66 examples, up to 86% yield) from

diarylacetylenes and aromatic aldehydes using I_2 as an oxidant (Scheme 1D). Of note, the structural diversity depends on the neighboring functional groups and thus is controllable. This feature could be used to generate diverse compound collection, which may have potential applications in drug discovery.

Initially, methyl 2-((2-aminophenyl)ethynyl)benzoate 1a and 4-chlorobenzaldehyde 2a were chosen as model substrates to optimize the reaction conditions (Table 1). Upon treatment



	$ \begin{array}{c} $	CI CI CI CI	t, additive, oxida ent, 90 °C, 3 h		o O N Sa
entry	catalyst	solvent	additive	oxidant	3a ^b (%)
1	$Pd(OAc)_2$	DCE	TsOH		16
2	CF ₃ COOAg	DCE	TsOH		12
3	$Cu(OTf)_2$	DCE	TsOH		37
4	CuI	DCE	TsOH		4
5	Ni ₂ SO ₄	DCE	TsOH		5
6	$Cu(OTf)_2$	DCE	AcOH		18
7	$Cu(OTf)_2$	DCE	TfOH		25
8	$Cu(OTf)_2$	toluene	TsOH		20
9	$Cu(OTf)_2$	DMF	TsOH		5
10	$Cu(OTf)_2$	MeCN	TsOH		6
11	$Cu(OTf)_2$	THF	TsOH		ND ^c
12	$Cu(OTf)_2$	MeOH	TsOH		5
13	$Cu(OTf)_2$	DCE	TsOH	I_2	85 (79) ^d
14	$Cu(OTf)_2$	DCE	TsOH	PhIO	6
15	$Cu(OTf)_2$	DCE	TsOH	PIDA	4
16	$Cu(OTf)_2$	DCE	TsOH	PIFA	9
17		DCE	TsOH	I_2	32
18	$Cu(OAc)_2$	DCE	TsOH	I_2	40
19	$Cu(acac)_2$	DCE	TsOH	I_2	58
20	$Cu(OTf)_2$	DCE	TsOH	I_2	75 ^e
21	$Cu(OTf)_2$	DCE	TsOH	I_2	55 ^f
-					

^{*a*}Reaction conditions: **1a** (0.5 mmol), **2a** (1 mmol), catalyst (20 mol %), solvent (2 mL), additive (0.25 mmol), oxidant (0.5 mmol), 90 °C, 3 h. ^{*b*}NMR yields determined by ¹H NMR using triphenyl-methane as an internal standard. ^{*c*}ND = not detected. ^{*d*}Isolated yield. ^{*e*}10 mol % of catalyst was used. ^{*f*}5 mol % of catalyst was used.

with 20 mol % Pd(OAc)₂ and 0.5 equiv of TsOH in DCE (2 mL) at 90 °C for 3 h, the desired quinoline-annulated tetracyclic compound 3a was obtained in 16% yield (Table 1, entry 1). We next screened other metal catalysts (Table 1, entries 2-5), showing that Cu(OTf)₂ was the optimal catalyst, giving 3a in 37% yield (Table 1, entry 3). When AcOH and TfOH were used as acidic additives, compound 3a was obtained in 18% and 25% yield, respectively (Table 1, entries 6 and 7). We also found that the solvent effect was remarkable: replacing DCE with toluene, DMF, MeCN, THF, and MeOH led to significantly diminished yields (Table 1, entries 8-12). To our satisfaction, addition of I₂ significantly improved the reactivity, giving 3a in 85% yield (Table 1, entry 13), while other hypervalent iodine reagents such as iodosobenzene (PhIO), (diacetoxyiodo)benzene (PIDA), and phenyliodine bis(trifluoroacetate) (PIFA) were found to be less efficient, giving 3a in <10% yields (Table 1, entries 13–16). It should be noted that in the absence of $Cu(OTf)_{2}$, compound 3a was obtained in 32% yield (Table 1, entry 17). Replacement of $Cu(OTf)_2$ with $Cu(OAc)_2$ or $Cu(acac)_2$ caused significantly decreased yields, compound **3a** was generated in 40% and 58% yields, respectively (Table 1, entries 18 and 19). A lower catalyst loading of 10 and 5 mol % furnished **3a** in 75% and 55% yield, respectively (Table 1, entries 20 and 21). According to the above optimizations, the optimal reaction conditions were methyl 2-((2-aminophenyl)ethynyl)benzoate **1a** (0.5 mmol), 4-chlorobenzaldehyde **2a** (1.0 mmol), $Cu(OTf)_2$ (20 mol %), TsOH (0.25 mmol), I_2 (0.5 mmol), DCE (2 mL), 90 °C, 3 h (Table 1, entry 13).

With the optimal reaction conditions in hand, we next examined the scope of 2-((2-aminophenyl)ethynyl)benzoates and aromatic aldehydes. As shown in Scheme 2A, the quinoline-annulated polyheterocyclic compounds were obtained in moderate to good yields (40-86%). For halogensubstituted aromatic aldehydes, the corresponding products 3a-3m were provided in good yields (56-80%). The halogen atoms were well tolerated and could be used for further functionalization. Mostly due to the steric hindrance, the compounds (e.g., 3b, 3e, 3g, 3j) bearing an ortho substituent were obtained in relatively lower yields. In general, both electron-deficient (-CF3, -CN, -CHO) and electron-rich (-Me, -Et, -iPr, -tBu, -OMe, -OH) aromatic aldehydes proceeded smoothly under the optimized reaction conditions and furnished the desired compounds 30-3ac in moderate to good yield (40-84%). Compounds 3s and 3aa bearing the oxidizable formaldehyde and phenolic OH groups were generated in relatively lower yields. In addition, the naphthyl aldehydes, 4-phenylbenzaldehyde, and heteroaromatic aldehydes were also compatible with our protocol and delivered the corresponding polyheterocyclic compounds 3ad-3ah in good yield (77-86%). To showcase the synthetic practicality, the reactions for the synthesis of compounds 3b and 3r were performed on a 1.0 mmol scale, providing the desired products in 60% and 66% yields, respectively. The crystal structure of 3a was also determined by the X-ray crystallographic analysis (CCDC: 1921863). We here demonstrate that diverse functional groups such as amine, ester, and aldehyde in substrates are well tolerated under the optimized reaction conditions and could be integrated in an efficient manner to form quinoline-annulated tetracyclic scaffolds. Besides, the scope of diarylacetylenes was also explored to showcase the generality of our protocol. As shown in Scheme 2B, various substituents on both phenyl rings of diarylacetylenes were well tolerated, giving the desired products 4a-4v in moderate to good yields (45-83%) under the optimal reaction conditions.

As shown in Scheme 2, the core scaffold depends on the functional ester group. Encouraged by the preceding results, it can be speculated that replacement of ester with other nucleophilic functional groups may afford novel polyheter-ocyclic scaffolds. As shown in Scheme 3A, diarylacetylenes bearing different functional groups (e.g., –CONHPh, –CH₂OH, phenolic OH, and amine) gave the corresponding products with high levels of structural diversity and novelty under the optimal conditions. Specifically, the quinoline-fused isoquinolinone scaffolds (5a,b) synthesized from 2-((2-aminophenyl)ethynyl)-*N*-phenylbenzamide widely exist in topoisomerase inhibitors and other bioactive molecules (Figure 1).^{34–36} For diarylacetylenes with the hydroxyl methyl and phenolic OH groups, the quinoline-fused isochrones 5c,d and quinoline-fused benzofurans 5e,f were obtained in moderate to good yields through an intramolecular *O*-attack

Scheme 2. Substrate Scope of Aldehydes and Diarylacetylenes for the Synthesis of Quinoline-Annulated Tetracyclic Scaffolds a,b



^aConditions: **1a** (0.5 mmol), **2** (1.0 mmol), Cu(OTf)₂ (20 mol %), TsOH (0.25 mol), I₂ (0.5 mmol), DCE (2 mL), 90 °C, 3 h. ^bIsolated yields. ^cConditions: **1a** (1 mmol), **2** (2.0 mmol), Cu(OTf)₂ (20 mol %), TsOH (0.5 mol), I₂ (1 mmol), DCE (5 mL), 90 °C, 3 h. ^d0.5 mmol of **2** was used.

pathway. Besides, we also found that *N*,*N*-dimethylamine could be employed as a nucleophile to produce the quinolineannulated indoles **5g**,**h** through the *N*-attack pathway. The pyridine-fused indole scaffold, also known as γ -carboline, is an interesting structural motif existed in natural products and bioactive molecules with diverse pharmacological activities.^{37–39} To further increase the scaffold diversity, the diarylacetylene **1b** bearing a terminal alcohol group was used, giving the desired tetrahydropyran-fused quinoline **6a** in 80% yield under the optimal conditions (Scheme 3B). The tricyclic heterofused quinoline **6a** is a key intermediate for the synthesis of druglike compound **A** with multitrypanosomatid pubs.acs.org/OrgLett

Scheme 3. Diversity-Oriented Synthesis of New Quinoline-Annulated Polyheterocyclic Scaffolds^{a,b}



^aConditions: 1 (0.5 mmol), 2 (1.0 mmol), $Cu(OTf)_2$ (20 mol %), TsOH (0.25 mol), I_2 (0.5 mmol), DCE (2 mL), 90 °C, 3 h. ^bIsolated yields. ^cConditions: 1 (0.5 mmol), 2 (1.0 mmol), $Cu(OTf)_2$ (20 mol %), TsOH (0.5 mol), I_2 (0.05 mmol), DCE (2 mL), 90 °C, 6 h.

activity.⁴⁰ This protocol provides an alternative method to synthesize compound A and analogues for biological testing. Similarly, compound 1c reacted with 4-hydroxylbenzaldehyde 2d smoothly, affording 7a in 77% yield (Scheme 3C). Of note, the electron-rich phenyl ring served as an intramolecular nucleophile for the cascade reactions, and only 10 mol % of I₂ was used. Further investigation on using electron-rich arenes as nucleophiles for intramolecular cascade reactions is undergoing in our lab and will be reported in due course. The crystal structures of 5h and 7a were further confirmed by the X-ray analysis (5h, CCDC: 1964272; 7a, CCDC: 1964273). Collectively, we envisioned that the copper catalysis developed herein achieved the diversity-oriented synthesis of new quinoline-fused polyheterocyclic frameworks present in natural products and bioactive molecules, and the structural diversity and novelty depended on the types of functional groups. It is anticipated that more novel scaffolds could be generated by installing other nucleophilic groups on the phenyl rings.

The control experiments were conducted to gain mechanistic insight into this cascade reaction. As shown in Scheme 4, the radical inhibitor 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) completely suppressed the reaction, while butylhydroxytoluene (BHT) also inhibited the reaction, giving the desired product **3a** in only 22% yield (detected by ¹H NMR using triphenylmethane as an internal standard), significantly lower than that under the optimal conditions. The data suggest that the Cu-catalyzed intramolecular cascade reactions involve a radical process.

Scheme 4. Control Experiments



Based on our observations and previous reports,⁴¹⁻⁴⁴ the proposed mechanism for the synthesis of quinoline-annulated polyheterocyclic scaffolds is shown in Scheme 5. Initially, the





intermediate M0 is generated in situ from methyl 2-((2aminophenyl)ethynyl)benzoate (1a) and benzaldehyde (2n) through TsOH-promoted condensation. Then the intermediate M0 undergoes a cooper salt promoted one-electron oxidation to form a radical cation M1. Subsequent intramolecular radical addition into the C \equiv C bond of M1 affords a radical M2, which then adds onto intramolecular imine through nucleophilic insertion to give a cyclized radical M3. The nitrogen radical would be trapped by iodine radical generated from the oxidation of iodide, generating the complex M4. Finally, a hydrogen iodide elimination step furnishes the alkenylation product 3n. Through the Cu-catalyzed cascade reactions, the diverse quinoline-annulated polyheterocyclic frameworks are efficiently constructed, in which one C-X (X = C, N, or O) bond, one C=N bond, one C-C bond, and two new ring systems are formed simultaneously.

In conclusion, we have developed the first $Cu(OTf)_2$ catalyzed intramolecular radical domino reactions that enable the efficient construction of structurally novel and diverse quinoline-annulated polyheterocyclic scaffolds from readily available diarylacetylenes and aromatic aldehydes. These polyheterocyclic scaffolds show high levels of structural diversity and novelty and have been found in numerous highly valuable natural products and bioactive molecules. Of note, the scaffold diversity, a central element in diversity-oriented synthesis, solely depends on the neighboring functional groups and thus is controllable. The compound library may have potential applications in new drug discovery.

ASSOCIATED CONTENT

3 Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.orglett.1c00129.

Experimental procedures, characterization data, and ¹H NMR, ¹³C NMR spectra for new compounds (PDF)

Accession Codes

CCDC 1921863 and 1964272–1964273 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/ cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Authors

- Bin Yu School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; orcid.org/0000-0002-7207-643X; Email: yubin@zzu.edu.cn
- Hong-Min Liu School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; orcid.org/0000-0001-6771-9421; Email: liuhm@ zzu.edu.cn

Authors

- Shuo Yuan School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; orcid.org/0000-0002-4273-5625
- Jingya Zhang School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China
- Danqing Zhang School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China
- Donghui Wei College of Chemistry, and Institute of Green Catalysis, Zhengzhou University, Zhengzhou 450001, China; orcid.org/0000-0003-2820-282X
- Jiahui Zuo School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China
- Jian Song School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.orglett.1c00129

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We acknowledge financial support from the National Natural Science Foundation of China (Nos. 81773562 and 81973177), the Program for Science & Technology Innovation Talents in Universities of Henan Province (No. 21HASTIT045), and the China Postdoctoral Science Foundation (Nos. 2018M630840, and 2019T120641).

REFERENCES

(1) Kiselev, E.; Dexheimer, T. S.; Pommier, Y.; Cushman, M. Design, synthesis and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents. *J. Med. Chem.* **2010**, *53*, 8716–8726.

(2) Oluyemisi, O. O.; Oriabure, A. E.; Adekunle, A. J.; Ramsay, K. S.; Shyyaula, S.; Choudhary, M. I. Bioassay-guided isolation of poliovirus-inhibiting constituents from zephyranthes candida. *Pharm. Biol.* **2015**, *53*, 882–887.

(3) Ouchani, F.; Jeanne, A.; Thevenard, J.; Helesbeux, J. J.; Wahart, A.; Letinois, I.; Duval, O.; Martiny, L.; Charpentier, E.; Devy, J. Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent. *Invest. New Drugs* **2015**, *33*, 75–85.

(4) Zupkó, I.; Réthy, B.; Hohmann, J.; Molnár, J.; Ocsovszki, I.; Falkay, G. Antitumor activity of alkaloids derived from amaryllidaceae species. *In Vivo* **2009**, *23*, 41–48.

(5) Liu, Y. Q.; Li, W. Q.; Morris-Natschke, S. L.; Qian, K.; Yang, L.; Zhu, G. X.; Wu, X. B.; Chen, A. L.; Zhang, S. Y.; Nan, X.; Lee, K. H. Perspectives on biologically active camptothecin derivatives. *Med. Res. Rev.* **2015**, *35*, 753–789.

(6) Rivaud, M.; Mendoza, A.; Sauvain, M.; Valentin, A.; Jullian, V. Short synthesis and antimalarial activity of fagaronine. *Bioorg. Med. Chem.* **2012**, *20*, 4856–4861.

(7) Pearce, A. N.; Appleton, D. R.; Babcock, R. C.; Copp, B. R. Distomadines A and B, novel 6-hydroxyquinoline alkaloids from the New Zealand ascidian, pseudodistoma aureum. *Tetrahedron Lett.* **2003**, *44*, 3897–3899.

(8) Cheng, N. T.; Guo, A.; Cui, Y. P. Intra-articular injection of Torin 1 reduces degeneration of articular cartilage in a rabbit osteoarthritis model. *Bone Joint Res.* **2016**, *5*, 218–224.

(9) Li, T. K.; Houghton, P. J.; Desai, S. D.; Daroui, P.; Liu, A. A.; Hars, E. S.; Ruchelman, A. L.; LaVoie, E. J.; Liu, L. F. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. *Cancer Res.* **2003**, *63*, 8400–8407.

(10) Meine, R.; Becker, W.; Falke, H.; Preu, L.; Loaec, N.; Meijer, L.; Kunick, C. Indole-3-carbonitriles as DYRK1A inhibitors by fragment-based drug design. *Molecules* **2018**, *23*, 64–87.

(11) Wu, H.; Wang, W.; Liu, F.; Weisberg, E. L.; Tian, B.; Chen, Y.; Li, B.; Wang, A.; Wang, B.; Zhao, Z.; McMillin, D. W.; Hu, C.; Li, H.; Wang, J.; Liang, Y.; Buhrlage, S. J.; Liang, J.; Liu, J.; Yang, G.; Brown, J. R.; Treon, S. P.; Mitsiades, C. S.; Griffin, J. D.; Liu, Q.; Gray, N. S. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. *ACS Chem. Biol.* **2014**, *9*, 1086–1091.

(12) Elsayed, M. S. A.; Griggs, B.; Cushman, M. Synthesis of benzo[1,6]naphthyridinones using the Catellani reaction. *Org. Lett.* **2018**, *20*, 5228–5232.

(13) Ji, F.; Li, X.; Wu, W.; Jiang, H. Palladium-catalyzed oxidative carbonylation for the synthesis of polycyclic aromatic hydrocarbons (PAHs). *J. Org. Chem.* **2014**, *79*, 11246–11253.

(14) Jha, R. R.; Saunthwal, R. K.; Verma, A. K. Stereoselective tandem synthesis of thiazolo fused naphthyridines and thienopyridines from *o*-alkynylaldehydes via Au(III)-catalyzed regioselective 6-*endo-dig* ring closure. Org. Biomol. Chem. **2014**, *12*, 552–556.

(15) Mao, X. F.; Zhu, X. P.; Li, D. Y.; Liu, P. N. Cu-catalyzed cascade annulation of alkynols with 2-azidobenzaldehydes: access to 6*H*-isochromeno[4,3-*c*]quinoline. *J. Org. Chem.* **2017**, *82*, 7032–7039. (16) Jia, R.; Li, B.; Liang, R.; Zhang, X.; Fan, X. Tunable synthesis of indolo[3,2-*c*]quinolines or 3-(2-aminophenyl)quinolines via aerobic/

anaerobic dimerization of 2-alkynylanilines. Org. Lett. 2019, 21, 4996-5001.

(17) Zhang, B.; Muck-Lichtenfeld, C.; Daniliuc, C. G.; Studer, A. 6-Trifluoromethyl-phenanthridines through radical trifluoromethylation of isonitriles. *Angew. Chem., Int. Ed.* **2013**, *52*, 10792–10795.

(18) Godoi, B.; Schumacher, R. F.; Zeni, G. Synthesis of heterocycles via electrophilic cyclization of alkynes containing heteroatom. *Chem. Rev.* **2011**, *111*, 2937–2980.

(19) Li, L.; Huang, D.; Shi, C.; Yan, G. 2-Alkynylaryl aldehydes (enynals) in organic synthesis. *Adv. Synth. Catal.* **2019**, *361*, 1958–1984.

(20) Jia, R.; Li, B.; Zhang, X.; Fan, X. Selective synthesis of 2-indolyl-3-oxoindolines or 2-(2-aminophenyl)quinolines through Cu(II)- or Bi(III)-catalyzed tunable dimerizations of 2-alkynylanilines. *Org. Lett.* **2020**, *22*, 6810–6815.

(21) Ling, F.; Song, D.; Chen, L.; Liu, T.; Yu, M.; Ma, Y.; Xiao, L.; Xu, M.; Zhong, W. Syntheses of *N*-alkyl 2-arylindoles from saturated ketones and 2-arylethynylanilines via Cu-catalyzed sequential dehydrogenation/aza-Michael addition/annulation cascade. *J. Org. Chem.* **2020**, *85*, 3224–3233.

(22) Yao, B.; Wang, Q.; Zhu, J. Palladium(II)-catalyzed intramolecular diamination of alkynes under aerobic oxidative conditions: catalytic turnover of an iodide ion. *Angew. Chem., Int. Ed.* **2012**, *51*, 5170–5174.

(23) Zhang, X.; Hou, W.; Zhang-Negrerie, D.; Zhao, K.; Du, Y. Hypervalent iodine-mediated intramolecular trans-aminocarboxylation and oxoaminocarboxylation of alkynes: divergent cascade annulations of isocoumarins under metal-free conditions. *Org. Lett.* **2015**, *17*, 5252–5255.

(24) Cai, J.; Wu, B.; Rong, G.; Zhang, C.; Qiu, L.; Xu, X. Goldcatalyzed bicyclization of diaryl alkynes: synthesis of polycyclic fused indole and spirooxindole derivatives. *Org. Lett.* **2018**, *20*, 2733–2736.

(25) Halim, R.; Scammells, P. J.; Flynn, B. L. Alternating iodoniummediated reaction cascades giving indole- and quinoline-containing polycycles. *Org. Lett.* **2008**, *10*, 1967–1970.

(26) Ding, D.; Zhu, G.; Jiang, X. Ligand-controlled palladium(II)catalyzed regiodivergent carbonylation of alkynes: syntheses of indolo[3,2-c]coumarins and benzofuro[3,2-c]quinolinones. *Angew. Chem., Int. Ed.* **2018**, *57*, 9028–9032.

(27) Yuan, S.; Zhang, D. Q.; Zhang, J. Y.; Yu, B.; Liu, H. M. Palladium-catalyzed ligand-free double cyclization reactions for the synthesis of 3-(1'-indolyl)-phthalides. *Org. Lett.* **2020**, *22*, 814–817.

(28) Yuan, S.; Yue, Y. L.; Zhang, D. Q.; Zhang, J. Y.; Yu, B.; Liu, H. M. Synthesis of new tetracyclic benzodiazepine-fused isoindolinones using recyclable mesoporous silica nanoparticles. *Chem. Commun.* **2020**, *56*, 11461–11464.

(29) Yuan, S.; Yu, B.; Liu, H. M. Palladium-catalyzed 'on-water' tandem cyclization reactions for the synthesis of biologically important 4-arylquinazolines. *Chem. - Eur. J.* **2019**, *25*, 13109–13113.

(30) Yuan, X.; Wang, S.; Cheng, J.; Yu, B.; Liu, H. M. Brønsted acidpromoted 'on-water' C(sp3)-H functionalization for the synthesis of isoindolinone/[1,2,4]triazolo[1,5-a]pyrimidine derivatives targeting the SKP2-CKS1 interaction. *Chin. Chem. Lett.* **2020**, *31*, 2465–2468.

(31) Wang, S.; Shen, D.; Zhao, L.; Yuan, X.; Cheng, J.; Yu, B.; Zheng, Y.; Liu, H. M. Discovery of [1,2,4]triazolo[1,5-*a*]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors. *Chin. Chem. Lett.* **2020**, *31*, 418–422.

(32) Wang, S.; Zhao, L.; Shi, X.; Ding, L.; Yang, L.; Wang, Z.; Shen, D.; Tang, K.; Li, X.; Mamun, M.; Li, H.; Yu, B.; Zheng, Y.; Wang, S.; Liu, H. M. Development of highly potent, selective, and cellular active triazolo[1,5-*a*]pyrimidine-based inhibitors targeting the DCN1–UBC12 protein-protein interaction. *J. Med. Chem.* **2019**, *62*, 2772–2797.

(33) Liu, Z.; Zhao, T.; Li, Z.; Sun, K.; Fu, Y.; Cheng, T.; Guo, J.; Yu, B.; Shi, X.; Liu, H. M. Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors. *Acta Pharm. Sin. B* **2020**, *10*, 1476–1491.

(34) Singh, S. K.; Ruchelman, A. L.; Li, T. K.; Liu, A.; Liu, L. F.; LaVoie, E. J. Nitro and amino substitution in the D-ring of 5-(2dimethylaminoethyl)- 2,3-methylenedioxy-5*H*-dibenzo[*c*,*h*][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. *J. Med. Chem.* **2003**, *46*, 2254–2257.

(35) Ruchelman, A. L.; Houghton, P. J.; Zhou, N.; Liu, A.; Liu, L. F.; LaVoie, E. J. 5-(2-Aminoethyl)dibenzo[$c_{,h}$][1,6]naphthyridin-6-ones: variation of N-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. J. Med. Chem. 2005, 48, 792–804.

(36) Liu, Q.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Hur, W.; Ahmed, T.; Sabatini, D. M.; Gray, N. S. Discovery of 9-(6aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 54, 1473–1480.

(37) Wang, N.; Switalska, M.; Wu, M. Y.; Imai, K.; Ngoc, T. A.; Pang, C. Q.; Wang, L.; Wietrzyk, J.; Inokuchi, T. Synthesis and in vitro cytotoxic effect of 6-amino-substituted 11*H*- and 11Me-indolo[3,2-*c*]quinolines. *Eur. J. Med. Chem.* **2014**, *78*, 314–323.

(38) Aroonkit, P.; Thongsornkleeb, C.; Tummatorn, J.; Krajangsri, S.; Mungthin, M.; Ruchirawat, S. Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents. *Eur. J. Med. Chem.* **2015**, *94*, 56–62.

(39) Falke, H.; Chaikuad, A.; Becker, A.; Loaec, N.; Lozach, O.; Abu Jhaisha, S.; Becker, W.; Jones, P. G.; Preu, L.; Baumann, K.; Knapp, S.; Meijer, L.; Kunick, C. 10-Iodo-11*H*-indolo[3,2-*c*]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. *J. Med. Chem.* **2015**, *58*, 3131–3143.

(40) Di Pietro, O.; Vicente-Garcia, E.; Taylor, M. C.; Berenguer, D.; Viayna, E.; Lanzoni, A.; Sola, I.; Sayago, H.; Riera, C.; Fisa, R.; Clos, M. V.; Perez, B.; Kelly, J. M.; Lavilla, R.; Munoz-Torrero, D. Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity. *Eur. J. Med. Chem.* **2015**, *105*, 120–137.

(41) Tang, S.; Liu, K.; Liu, C.; Lei, A. Olefinic C-H functionalization through radical alkenylation. *Chem. Soc. Rev.* **2015**, *44*, 1070–1082.

(42) Peng, Y.; Zhang, F.; Qin, T. T.; Xu, C. L.; Yang, L. Regio- and stereo-selective decarbonylative alkylative arylation of terminal alkynes with aliphatic aldehydes and arenes via dual C-H bond functionalization. *Org. Chem. Front.* **2019**, *6*, 3597–3602.

(43) Hasegawa, E.; Tateyama, M.; Nagumo, R.; Tayama, E.; Iwamoto, H. Copper(II)-salt-promoted oxidative ring-opening reactions of bicyclic cyclopropanol derivatives via radical pathways. *Beilstein J. Org. Chem.* **2013**, *9*, 1397–1406.

(44) Ho, H. E.; Oniwa, K.; Yamamoto, Y.; Jin, T. N-methyl transfer induced copper-mediated oxidative diamination of alkynes. *Org. Lett.* **2016**, *18*, 2487–2490.